AB1096 IMPROVEMENT IN KEY PSORIATIC ARTHRITIS CORE DOMAINS WITH GUSELKUMAB TREATMENT IN AN ENRICHED POPULATION OF ACR20 NON-RESPONDERS AT WEEK 24: POST HOC ANALYSIS OF TWO PHASE 3 STUDIES

Abstract

BackgroundDespite available PsA treatments, a portion of PsA patients (pts) does not achieve improvements in PsA signs and symptoms according to the American College of Rheumatology (ACR) response criteria.ObjectivesUsing data...